Weight, glucose parameters, and adverse effect assessment inform protocol adjustments
These medications mimic GLP-1, a naturally occurring hormone, and help you feel full for longer after eating as well as manage your blood sugar
Glucagon-like peptide 1 receptor agonists (GLP-1RAs), traditionally used in the treatment of type 2 diabetes, are becoming increasingly appreciated for their diverse applications
Consequently, although obesity affects hundreds of millions of people globally, GLP-1 therapies currently reach only a small fraction of eligible patients, underscoring the substantial unmet need for more convenient, scalable, and accessible treatment options
Importantly, this mechanistic framework is increasingly supported by large-scale clinical outcome data
Best medical experience I've had in years." Terika M